Midcareer Investigator Award

描述（由申请人提供）：该申请旨在为Matthew Smith博士提供受保护的时间，以致力于以患者为导向的研究，并作为临床研究员和初级教师的有效研究导师。候选人是马萨诸塞州总医院泌尿生殖肿瘤临床研究主任，丹娜-法伯哈佛癌症中心（DF/HCC）泌尿生殖恶性肿瘤临床研究联合主任。他的临床研究项目主要集中在癌症生存、骨转移的预防和治疗以及晚期前列腺癌的新疗法。他在以患者为导向的研究、独立的同行评审资助和成功的指导方面有着良好的记录。此申请的时间恰逢候选人以患者为导向的研究项目的新方向，额外成功的资助申请，最近选择的新实习生，以及计划扩大的指导活动。

DESCRIPTION (provided by applicant): This Midcareer Investigator Award application seeks support to provide Dr. Matthew Smith with protected time to devote to patient-oriented research and to act as an effective research mentor for clinical fellows and junior faculty. The candidate is the Clinical Research Director in Genitourinary Oncology at Massachusetts General Hospital and Co-Director of the Clinical Research in Genitourinary Malignancies for Dana-Farber Harvard Cancer Center (DF/HCC). His clinical research program focuses on cancer survivorship, prevention and treatment of bone metastases, and novel therapies for advanced prostate cancer. He has a strong record of patient-oriented research, independent peer-reviewed funding, and successful mentoring. The timing of this application coincides with the new directions in the candidate's patient-oriented research program, additional successful grant applications, recent selection of a new trainee, and the planned expansion of mentoring activities. The broad long-term objective of this application is to advance both the patient-oriented research program and mentoring activities of the candidate. The Specific Aims are: 1. To decrease disease and treatment-related morbidity in cancer survivors, to treat and prevent bone metastases, and to develop novel therapies for advanced prostate cancer. 2. To evaluate mechanism(s) of treatment-related diabetes and cardiovascular disease in prostate cancer survivors, a new direction in the candidate's patient-oriented research program. 3. To mentor new investigators in patient-oriented research. This research program may advance public health by developing new strategies to treat prostate cancer and to prevent bone metastases, a major cause of prostate cancer morbidity. In addition, this research program may help decrease the burden of cancer treatment for prostate cancer survivors.